

十七烷-9-基-8-((2-羟乙基)(6-氧代-6-((十一烷氧基)己基)氨基)辛酸酯)
产品简称:SM-102(HUO)CAS no.:2089251-47-6| CAS no. | 分子量(Mp) | 产品编码 |
| 2089251-47-6 | 710 | 06040008800 |
该产品受到第三方专利的保护,本公司不供应该产品,仅:(a)提供与专利不冲突的一般性技术咨询;(b)在有第三方专利权人许可的前提下接受定制和CMO服务。如有需求可留言联系我司。
DMF备案登记号:038143;CDE备案登记号:F20210000505
查库存 / 立即抢购:因官网暂不支持直接下单,可点击链接跳转至商城选购,一键锁定现货
即刻跳转
HUO | 十七烷-9-基-8-((2-羟乙基)(6-氧代-6-((十一烷氧基)己基)氨基)辛酸酯)
相关文献:
1. Wan J, Wang C, Wang Z, et al. CXCL13 promotes broad immune responses induced by circular RNA vaccines. Proc Natl Acad Sci U S A. 2024;121(44):e2406434121. doi:10.1073/pnas.2406434121
2. Wang L, Wan J, He W, et al. IL-7 promotes mRNA vaccine-induced long-term immunity. J Nanobiotechnology. 2024;22(1):716. Published 2024 Nov 16. doi:10.1186/s12951-024-02993-5
3. Tong H, Ma Z, Yu J, et al. Optimizing Peptide-Conjugated Lipid Nanoparticles for Efficient siRNA Delivery across the Blood-Brain Barrier and Treatment of Glioblastoma Multiforme. ACS Chem Biol. 2025;20(4):942-952. doi:10.1021/acschembio.5c00039
4. Shao X, Liu L, Weng C, et al. Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy. Vaccines (l). 2025;13(5):448. Published 2025 Apr 24. doi:10.3390/vaccines13050448
5. Deng X, Yang Y, Gan L, et al. Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge. Pharmaceutics. 2025;17(2):157. Published 2025 Jan 24. doi:10.3390/pharmaceutics17020157
6. Zhu C, Roa N, Neathery E et al. Comparative technical and operational assessment of current and emerging bench-scale lipid nanoparticle platforms for production of mRNA vaccines [version 1]. VeriXiv 2025, 2:96 (https://doi.org/10.12688/verixiv.982.1)
7. Ye T, Zhou J, Guo C, et al. Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus. Cell Rep. 2024;43(6):114269. doi:10.1016/j.celrep.2024.114269
8. Cheng X, Zheng X, Tao K, et al. Freezing induced incorporation of betaine in lipid nanoparticles enhances mRNA delivery. Nat Commun. 2025;16(1):4700. Published 2025 May 20. doi:10.1038/s41467-025-60040-9
9. Liu S, Wen Y, Shan X, et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat Commun. 2024;15(1):9471. Published 2024 Nov 2. doi:10.1038/s41467-024-53914-x
10. Kozlova A, Pateev I, Shepelkova G, et al. A Cap-Optimized mRNA Encoding Multiepitope Antigen ESAT6 Induces Robust Cellular and Humoral Immune Responses Against Mycobacterium tuberculosis. Vaccines (l). 2024;12(11):1267. Published 2024 Nov 9. doi:10.3390/vaccines12111267
11. Wang H, Peng Q, Dai X, et al. A SARS-CoV-2 EG.5 mRNA vaccine induces a broad-spectrum immune response in mice. MedComm (2020). 2025;6(1):e779. Published 2025 Jan 2. doi:10.1002/mco2.779
12. Cao H, Zhang X, Cheng J, et al. A QS21 + CpG-Adjuvanted Trivalent HSV-2 Vaccine and Trivalent HSV-2 mRNA Vaccine Induce a Strong Immune Response, Protect Against HSV-2 Infection, and Cross-Protect Against HSV-1 Infection in Mice. Vaccines (l). 2025;13(5):497. Published 2025 May 6. doi:10.3390/vaccines13050497
13. Zhang S, Wang X, Zhao T, Yang C, Huang L. Development and Evaluation of the Immunogenic Potential of an Unmodified Nucleoside mRNA Vaccine for Herpes Zoster. Vaccines (l). 2025;13(1):68. Published 2025 Jan 13. doi:10.3390/vaccines13010068
14. Wang Z, Tian C, Zhu J, et al. Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens. J Nanobiotechnology. 2025;23(1):55. Published 2025 Jan 29. doi:10.1186/s12951-025-03156-w
15. Widayat, Wahyu & Hardianto, Ari & Hidayati, Rahma & Neni, Nurainy & Burhanudin, Muhammad & Yusuf, Muhammad & Subroto, Toto. (2025). The Effect of Mixed Lipid Concentrations and Sucrose on the Size of the Lipid Nanoparticles Containing mRNAs. Trends in Sciences. 22. 8985. 10.48048/tis.2025.8985.
16. Jeon JH, Kim S, Kim SY, et al. Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants. Front Immunol. 2025;16:1597417. Published 2025 May 28. doi:10.3389/fimmu.2025.1597417
17. Tong H, Ma Z, Li D, et al. Tuning the polyethylene glycol-lipid anchor length of lipid nanoparticles to enhance brain-targeted siRNA delivery. Acta Biomater. Published online October 11, 2025. doi:10.1016/j.actbio.2025.10.018
18. Xiao C, Liu X, Liu P, et al. Oncogenic roles of young human de novo genes and their potential as neoantigens in cancer immunotherapy. Cell Genom. 2025;5(9):100928. doi:10.1016/j.xgen.2025.100928
19. Zheng X, Liu B, Ni P, et al. Development and application of an uncapped mRNA platform. Ann Med. 2025;57(1):2437046. doi:10.1080/07853890.2024.2437046
20. Liu D, Wang X, Xu L, et al. Screening lipid nanoparticles using DNA barcoding and qPCR. Colloids Surf B Biointerfaces. 2025;251:114598. doi:10.1016/j.colsurfb.2025.114598
21. Abidin, Muhamad & Yusuf, Muhammad & Widayat, Wahyu & Subroto, Toto & Neni, Nurainy & Hardianto, Ari. (2023). The Implementation of Response Surface Methodology in the Optimization of Lipid Nanoparticle Preparation for Vaccine Development. Trends in Sciences. 21. 7142. 10.48048/tis.2024.7142.
22. Li W, Li Y, Li J, et al. All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer. Adv Sci (Weinh). 2024;11(22):e2309770. doi:10.1002/advs.202309770
23. Li M, Yi J, Lu Y, et al. Modified PEG-Lipids Enhance the Nasal Mucosal Immune Capacity of Lipid Nanoparticle mRNA Vaccines. Pharmaceutics. 2024;16(11):1423. Published 2024 Nov 7. doi:10.3390/pharmaceutics16111423
24. Yu W, Chen X, Chen Q, et al. A Safe and Broad-spectrum SARS-CoV-2 mRNA Vaccine with a New Delivery System for In-situ . Virol Sin. Published online September 4, 2025. doi:10.1016/j.virs.2025.09.001
25. Li H, Hu Y, Li J, et al. Intranasal prime-boost RNA vaccination elicits potent T cell response for lung cancer therapy. Signal Transduct Target Ther. 2025;10(1):101. Published 2025 Mar 24. doi:10.1038/s41392-025-02191-1
26. Yi J, Lu Y, Liu N, et al. Chitosan and mannose-modified dual-functional mRNA-LNP vaccines for robust systemic and mucosal immune responses. J Control Release. 2025;384:113891. doi:10.1016/j.jconrel.2025.113891
27. Shi R, Liu X, Wang Y, et al. Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size. Hum Vaccin Immunother. 2024;20(1):2342592. doi:10.1080/21645515.2024.2342592
28. Lu Y, Yang Y, Yi J, et al. Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-d pulmonary mucosal vaccination. Mater Today Bio. 2025;32:101813. Published 2025 May 4. doi:10.1016/j.mtbio.2025.101813
29. Lv K, Yu Z, Wang J, et al. Discovery of Ketal-Ester Ionizable Lipid Nanoparticle with Reduced Hepatotoxicity, Enhanced Spleen Tropism for mRNA Vaccine Delivery. Adv Sci (Weinh). 2024;11(45):e2404684. doi:10.1002/advs.202404684
30. Lee Y, Jeong M, Lee G, et al. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics. Biomater Res. 2024;28:0017. Published 2024 May 22. doi:10.34133/bmr.0017
31. Na GS, Joo JU, Lee JY, et al. Full-cycle study on developing a novel structured micromixer and evaluating the nanoparticle products as mRNA delivery carriers. J Control Release. 2024;373:161-171. doi:10.1016/j.jconrel.2024.07.019
32. Dong L, Wang J, Xia Q. Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons. Nat Commun. 2025;16(1):7825. Published 2025 Aug 22. doi:10.1038/s41467-025-62981-7
33. Wan J, Wang Z, Wang L, et al. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses. mBio. 2024;15(1):e0177523. doi:10.1128/mbio.01775-23
34. Tang S, Huang L, Ge J, et al. Influence of salt solution on the physicochemical properties and in vitro/ in vivo of mRNA/LNP. J Nanobiotechnology. 2025;23(1):223. Published 2025 Mar 19. doi:10.1186/s12951-025-03318-w
35. Yu, Juntao & Li, Qian & Luo, Shenggen & Wang, Xiaona & Cheng, Qiang & hu, Rongkuan. (2024). Targeted LNPs deliver mRNA encoding IL-15 superagonists to balance efficacy and toxicity in cancer therapy. 10.1101/2024.01.11.575299.
36. Sun, Zhen & Liu, Yuxiao & Zhang, Haoyi & Ge, Ting & Pan, Yuting & Liu, Yang & Wu, Miaomiao & Shan, Tao & Wu, Qi & Zhu, Guoqiang & Chen, Kangming. (2025). Next-Generation saRNA Platforms: Systematic Screening and Engineering Enhances Superior Protein and Organ-Specific Targeting for RNA Therapeutics. 10.1101/2025.03.30.644708.
37. Luo C, Li Y, Liu H, et al. Intracellular trafficking of lipid nanoparticles is hindered by cholesterol. Int J Pharm. 2025;671:125240. doi:10.1016/j.ijpharm.2025.125240
38. Chen, Xiaoxia & Li, Mengrong & Jiang, Fan & Hong, Liang & Liu, Zhuo. (2024). Revealing a Correlation between Structure and in vitro Activity of mRNA Lipid Nanoparticles. 10.1101/2024.09.01.610730.
39. Liu X, Li Z, Li X, et al. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice. Nat Commun. 2024;15(1):8932. Published 2024 Oct 16. doi:10.1038/s41467-024-53242-0
40. Joo, Jeong-Un & Na, Gi-Su & Sharma, Vikas & Mottafegh, Amirreza & Kim, Dongpyo. (2024). Ultrafast continuous flow-dialysis for nanoparticle-d drug delivery systems via microfluidic-multiple buffer injector. Chemical Engineering Journal. 500. 156631. 10.1016/j.cej.2024.156631.
41. Ma X, Liu S, Zhang S, et al. Engineering of mRNA vaccine platform with reduced lipids and enhanced efficacy. Nat Commun. 2025;16(1):8913. Published 2025 Oct 7. doi:10.1038/s41467-025-63965-3
42. Chen YC, Lee YL, Lee CA, Lin TY, Hwu EE, Cheng PC. Development of a Lipid-encapsulated TGFβRI-siRNA Drug for Liver Fibrosis Induced by Schistosoma mansoni. PLoS Negl Trop Dis. 2024;18(9):e0012502. Published 2024 Sep 12. doi:10.1371/journal.pntd.0012502
43. Francis JA, Wright L, Oerlemans SK, van Wegen R, Falconer RJ. Idiosyncratic behaviour of pegylated lipid nanoparticles used in RNA delivery: A dynamic light scattering study. Int J Pharm. Published online September 20, 2025. doi:10.1016/j.ijpharm.2025.126196
44. Ren L, Zhao Z, Chao Y, et al. Optimization of Lipid Nanoparticles with Robust Efficiency for the Delivery of Protein Therapeutics to Augment Cancer Immunotherapy. Adv Sci (Weinh). 2025;12(17):e2500844. doi:10.1002/advs.202500844
45. Chen, Xiaoxia & Ye, Yongfeng & Li, Mengrong & Zuo, Taisen & Xie, Zhenhua & Ke, Robin & Cheng, He & Hong, Liang & Liu, Zhuo. (2024). Structural Characterization of mRNA Lipid Nanoparticles in the Presence of Intrinsic Drug-free Lipid Nanoparticles. 10.1101/2024.09.27.614859.
46. Wang L, Wan J, He W, et al. IL-7 promotes mRNA vaccine-induced long-term immunity. J Nanobiotechnology. 2024;22(1):716. Published 2024 Nov 16. doi:10.1186/s12951-024-02993-5
关键词:moderna疫苗新冠疫苗辅料HUOHeptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate)SM102- 06030503502 06030503504 06030503506α-生物素-ω-1,2-二硬脂酸-3-磷脂酰乙醇胺聚乙二醇(铵盐)DSPE-PEG-Biotin
- 06030200502聚乙二醇单甲醚化-1,2-二油酰磷脂酰乙醇胺mPEG-DOPE
- 06030503102α-二苯并环辛炔-ω-1,2-二硬脂酸-3-磷脂酰乙醇胺聚乙二醇DSPE-PEG-DBCO
- D2041802 D2041804 D2041806二肉豆蔻酰甘油-聚乙二醇-活性酯DMG-PEG-NHS
- 二油酰磷脂酰乙醇胺-聚乙二醇-马来酰亚胺DOPE-PEG-MAL1480542-74-2
- 二油酰磷脂酰乙醇胺-聚乙二醇-活性酯DOPE-PEG-NHS
- D2023502 D2023504 D2023506甲氧基聚乙二醇-腙键-硬脂酰基磷脂酰乙醇胺mPEG-HYD-DSPE
- D2023402 D2023404 D2023406甲氧基聚乙二醇-酮羧硫醇-二硬脂酰基磷脂酰乙醇胺mPEG-TK-DSPE
- D2023302 D2023304 D2023306甲氧基聚乙二醇-双硫键-二硬脂酰基磷脂酰乙醇胺mPEG-SS-DSPE
- D2023202 D2023204 D2023206二硬脂酰基磷脂酰乙醇胺-聚乙二醇-半乳糖DSPE-PEG-半乳糖
















